The acute subjective effects of serotonin (5-HT)2A receptor stimulation with lysergic acid diethylamide (LSD) in humans are mostly positive. However, negative effects such as anxiety, paranoid thinking or loss of trust towards other people are common effects, depending on the dose administered, the personality traits of the person consuming it (set), or the environment in which LSD is taken (setting). Negative psychedelic effects may cause acute distress to the subject and acute anxiety has been linked to less favourable long-term outcomes in patients experimentally treated with LSD or similar substances for the treatment of depression. The 5-HT and oxytocin releaser 3,4-methylenedioxymethamphetamine (MDMA) reliably induces positive mood up to euphoria, comfort, empathy, and feelings of trust. If administered in combination with LSD, MDMA may increase positive subjective drug effects including positive mood, empathy, and trust and reduce negative emotions and anxiety associated with LSD and overall produce a more positive over negative experience. The present study will assess subjective and autonomic effects of LSD alone and in combination with MDMA.
LSD is a so-called "classic" or serotonergic hallucinogen or psychedelic. Its psychedelic effects are mainly attributed to its potent partial serotonin (5-HT) 5-HT2A receptor agonism. The effects of LSD have been frequently investigated in the past in both healthy participants and patients. Several of these studies described robust and sustained effects of LSD in patients suffering from addiction, anxiety and depression. The acute subjective effects elicited by LSD are mostly positive in humans. However, psychedelic substances like LSD may also cause unpleasant subjective effects like negative thoughts, rumination, anxiety, panic, paranoia, loss of trust towards other people and perceived loss of control, depending on the dose of LSD used, the personality traits of the person consuming it (i.e. 'set'), the environment in which it is consumed (i.e. 'setting'), and other factors yet to be determined. Acute negative psychological effects are considered the main risk of psychedelic substance use in humans. Inducing an overall positive acute response to the psychedelic is critical because several studies showed that a more positive experience is predictive of a greater therapeutic long-term effect of the psychedelic. Therefore, there is a need for methods which are capable of reducing bad drug effects while enhancing good drug effects to optimize a psychedelic experience. The present study uses 3,4-methylenedioxymethamphetamine (MDMA) as a pharmacological tool to optimize LSD's effects profile by inducing positive mood. MDMA is an amphetamine derivative which, unlike prototypical amphetamines, predominantly enhances serotonergic neurotransmission via release of 5-HT through the serotonin transporter (SERT). Furthermore, MDMA is known to trigger oxytocin release which may contribute to its effects to increase trust, prosociality, and enhanced empathy. The state of well-being induced by MDMA including increased activation and emotional excitation is known to be associated with a better response to psychedelics. Due to its psychological profile, MDMA could be a reliable pharmacological tool to serve as an optimizer of a psychedelic experience by inducing positive emotions.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
TRIPLE
Enrollment
24
A moderate dose of 100 μg LSD will be administered.
A moderate dose of 100 mg MDMA will be administered.
Pure alcohol instead of an alcoholic solution containing LSD
Mannitol capsules instead of capsules containing MDMA
University Hospital Basel, Clinical Trial Unit
Basel, Canton of Basel-City, Switzerland
Acute subjective effects I
Visual Analog Scales (VAS) assessing the intensity and duration of subjective effects on a scale from 0% - 100% with higher scores representing more intense effects
Time frame: 12 months
Acute subjective effects II
Adjective Mood Rating Scale (AMRS) assesses the occurrence and intensity of 60 moods on a 4-point Likert scale ranging from "not at all" to "extremely"
Time frame: 12 months
Acute subjective effects III
5 Dimensions of Altered States of Consciousness (5D-ASC) consisting of 94 items to be rated on a visual analog scale (0-100 mm), with higher values indicating stronger effects
Time frame: 12 months
Autonomic effects I
Assessed 18 times on each study day via systolic and diastolic blood pressure
Time frame: 12 months
Autonomic effects II
Assessed 18 times on each study day via heart rate
Time frame: 12 months
Autonomic effects III
Assessed 18 times on each study day via tympanic body temperature
Time frame: 12 months
Plasma levels of LSD
Assessed 18 times on each study day via blood samples
Time frame: 12 months
Plasma levels of MDMA
Assessed 18 times on each study day via blood samples
Time frame: 12 months
Plasma levels of blood-derived neurotrophic factor (BDNF)
Assessed 21 times on each study day via blood samples
Time frame: 12 months
Plasma levels of oxytocin
Assessed 4 times on each study day via blood samples
Time frame: 12 months
Psychological Insight Questionnaire
Assesses the degree of psychological insight caused by a psychedelic experience through 14-items to be answered on a 6-point Likert scale ranging from 0 ("not at all") to 5 ("extremely")
Time frame: 12 months
States of Consciousness Questionnaire
Assesses the emergence and intensity of phenomenons occurring in altered states of consciousness on a 6-point Likert scale ranging from 0 ("not at all") to 5 ("extremely")
Time frame: 12 months
Spiritual Realms Questionnaire
Assesses the spiritual phenomenons elicited by psychedelic substances through 11 main questions to be answered on a total of 65 sub-ordered 100mm visual analog scales
Time frame: 12 months
Effect moderation through personality traits I
Assessed via NEO-Five-Factor-Inventory (NEO-FFI)
Time frame: Baseline
Effect moderation through personality traits II
Assessed via Freiburger Personality Inventory (FPI)
Time frame: Baseline
Effect moderation through personality traits III
Assessed via Saarbrücker Personality Questionnaire (SPF)
Time frame: Baseline
Effect moderation through personality trait IV
Assessed via HEXACO personality inventory
Time frame: Baseline
Effect moderation through personality trait V
Assessed via Defense Style Questionnaire (DSQ-40)
Time frame: Baseline
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.